-+ 0.00%
-+ 0.00%
-+ 0.00%

Whitehawk Q1 net loss turns to USD 22.2 million

PUBT·05/07/2026 12:04:46
Listen to the news
Whitehawk Q1 net loss turns to USD 22.2 million
  • Whitehawk Therapeutics posted a net loss of USD 22.2 million, swinging from net income of USD 73 million a year earlier.
  • Research and development expenses climbed to USD 17.2 million from USD 8.8 million, including USD 5.3 million of development milestone expenses under a license agreement with WuXi Biologics.
  • Cash, cash equivalents, short-term investments fell to USD 123 million at March 31 from USD 145.7 million at Dec. 31; cash runway seen funding operations into 2028.
  • Phase 1 dose-escalation studies for HWK-007 and HWK-016 continued enrolling; IND submission for HWK-206 remains on track for mid-2026 with Phase 1 recruitment planned to start in Q3 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Whitehawk Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605070800PR_NEWS_USPR_____LA53107) on May 07, 2026, and is solely responsible for the information contained therein.